Indiana Psychedelic Society

07/30/2026

03/11/2026

Colorado introduced a bill this month that could quietly reshape how the US approaches ibogaine research — and it has some provisions worth paying attention to.
HB26-1325 would create up to five state-supported ibogaine research pilot sites, focused on treating addiction, PTSD, and other mental health conditions. Veterans are specifically named in the bill's legislative declaration, reflecting growing interest in ibogaine as a treatment for combat-related trauma.
The provision drawing the most attention is an Indigenous benefit-sharing requirement. Any organization seeking to run a pilot site — or eventually cultivate, manufacture, or administer ibogaine in Colorado — would be required to develop a plan that benefits the communities in Central Africa who have traditionally worked with the plant.
It's an unusual and genuinely progressive requirement. Whether it has real teeth will depend entirely on how the rules get written.
We dug into the full bill — including a sourcing gap that nobody seems to be talking about yet. Read it at the link. 👇

01/23/2026

Go New Jersey!

MUSHROOM THERAPY: In one of his last acts in office, former Gov. Phil Murphy signed a new law that legalized psilocybin – otherwise known as “Magic Mushrooms” – for medical use.

https://bit.ly/4qasRAZ

01/14/2026

Liberate the plants... The government does not need to be involved with Nature - Aikutzi Valadez

12/17/2025

12/16/2025

On Tuesday December 9, CPCR Director Dr. Fred Barrett and Assistant Professor Dr. Brandon Weiss took part in a roundtable exchange among VA representatives, researchers, and veteran groups organized by the Senate Committee on Veteran Affairs. The CPCR was honored to share our perspective on the potential and risks related of psychedelic therapies as a treatment for posttraumatic stress (PTS), depression, and other invisible wounds our nation's Veterans suffer. Members of the roundtable were able to share with four Senators and two Representatives over the course of the event, reflecting the attention that is now being paid to psychedelic therapeutics at the highest levels of federal government. Most inspiring was the commitment exhibited by everyone in the room to reject the complacency reflected in rising rates of su***de and PTS (many in the room had been personally affected by the deaths of friends and family members), and enact a higher standard of care for Veterans through serious investment of resources in researching the safety, effectiveness, and implementation of these innovative therapies. The CPCR, which has been studying psychedelic therapies for over two decades, will be publishing findings from its PTSD Study in 2026 and continuing to complete its ongoing Veteran-focused M**A + Psilocybin co-administration study in 2026.